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Background: The prevalence of cardiovascular disease (CVD) and inflammation is high in patients with chronic
kidney disease (CKD). Adiponectin (ADPN) is an adipocytokine that may have significant anti-inflammatory and anti-
atherosclerotic effects. Low adiponectin levels have previously been found in patients with high risk for CVD.
Methods: On seventy eight advanced CKD (stages 4 and 5) pediatric patients undergoing maintenance
hemodialysis( MHD) or conservative treatment (CT) the following parameters were studied: body mass index, left
ventricular mass index(LVMI), serum adiponectin , cholesterol, HDL-cholesterol, high sensitivity C-reactive protein (hs
CRP),interleukin 6(IL6) and single-nucleotide polymorphisms (SNPs) in the ADIPOQ gene at positions 45, and 276.
Seventy age-and gender-matched healthy subjects served as control subjects.
Results: Markedly (P = 0.01) elevated plasma adiponectin levels were observed in CKD patients, especially CT
patients, compared to control subjects. The wild type of ADIPOQ 45T > G (T) allele is the main gene for patients
and controls. MHD and CT patients had significantly higher frequency of the TT genotypes of +276G > T gene
(P= 0.04) compared with control subjects. A significant positive correlation was observed between plasma
adiponectin and IL6 level, whereas negative correlations were found between adiponectin level, cholesterol, HDL
cholesterol and hs CRP. In a stepwise backward multiple regression model only IL6 (P= 0.001) was independently
associated with plasma adiponectin levels. The adiponectin gene the 276 GT+TT genotypes were associated with a
higher level of adiponectin .
Conclusions: The present study demonstrated that ADPN is related to several metabolic and inflammatory CV risk
factors in a manner consistent with the hypothesis that this protein might have a protective role against these
factors. We observed an association between the +276G>T SNP in the adiponectin gene and CKD in children.
Genetic variation of +276 gene seemed to have a positive impact on circulating adiponectin levels in CKD patients.
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Endothelial dysfunction is one of the most serious compli-
cations that occur in children with chronic kidney disease
(CKD). It is caused by nontraditional risk factors such
as inflammation and oxidative stress [1]. Adiponectin
(ADPN) seems to play a protective role in vascular injury,
as it modulates endothelial inflammatory response in vitroCorrespondence: manal_elshmaa@hotmail.com
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reproduction in any medium, provided the or[2] and inhibits endothelial nuclear factor kappa B (NF-kB)
signaling [3].
CKD is a unique condition in that exceedingly high inci-
dence of enhanced cardiovascular disease (CVD) events
[4-6] [increasing from conservative (CT) to maintenance
hemodialysis (MHD) treatment [7]] is paradoxically asso-
ciated with elevated plasma adiponectin. Although Zoccali
et al. [7] have questioned the previously reported protective
cardiovascular impact of adiponectin in earlier stages of
renal disease [5], available evidence indicates that highest
total adiponectin increments are associated with loweral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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observations suggest that adiponectin-dependent meta-
bolic and cardiovascular protection is preserved in
advanced chronic uremia, although its effectiveness could
be blunted by additional CKD-associated alterations and
risk factors. CKD-associated hyperadiponectinemia could
be due at least in part to reduced glomerular filtration rate
and passive accumulation [10].
Adiponectin is a 30-kD adipocyte complement-related
cytokine encoded by the adipose most abundant gene tran-
script 1 (apM1), which is located in a diabetes susceptibil-
ity locus on chromosome 3q27 [11]. Adiponectin acts
peripherally and circulates in human plasma at high levels
(about 0.01% of the total plasma protein pool) [12]. This
protein is thought to have significant anti-inflammatory,
insulin-sensitizing and anti-atherogenic effects [13,14].
Adiponectin levels have a strong genetic component,
with an additive genetic heritability of 46% [15]. The adi-
ponectin gene (ADIPOQ) consists of three exons and
two introns spanning a 17-kb region [16]. The ADIPOQ
was found to be the only major gene responsible for
plasma adiponectin [17]. Two single nucleotide poly-
morphisms (SNPs) in ADIPOQ gene were found to be
associated with type 2 diabetes in Japanese individuals
[18]. One of the SNPs (TG in codon 276) was also asso-
ciated with lower plasma adiponectin levels, although
this relationship was limited to obese subjects [19]. An-
other SNP (T>G at nucleotide 94: SNP 45) was found to
be associated with insulin resistance, and dyslipidemia in
a German population [20].A haplotype defined by these
two SNPs has also been associated with components of
the insulin resistance syndrome in Caucasians [20].
Low plasma levels of adiponectin have been documen-
ted in various non renal patient populations at risk of
CVD, such as in patients with, essential hypertension
[21,22], and coronary artery disease [23,24]. No data on
the impact of genetic variations are yet available in
pediatric end stage renal disease (ESRD) patients.
The objectives of the present study were, therefore, to re-
late plasma levels of adiponectin in pediatric CKD patients
to body mass index (BMI), inflammatory biomarkers and
estimated glomerular filtration rate (eGFR), secondly to in-
vestigate two SNPs (+276 G>T (rs1501299) and +45 T>G
(rs2241766)) in ADIPOQ gene, their possible association
with CKD and their impact on plasma adiponectin levels.
Methods
Seventy eight Egyptian pediatric patients with advanced
CKD [stages 4 and 5 based on eGFR according to the Na-
tional Kidney Foundation classification [National Kidney
Foundation, 2002], [25] were included in the study. They
were divided into two groups undergoing CT (defined as se-
vere reduction in GFR ranged between 15 and 29 mL/min.
per 1.73 m2) (n=32) or MHD (defined as ESRD with GFRranged between5-15 mL/min. per 1.73 m2) (n=46). MHD
children were selected from the hemodialysis unit of the
Center of Pediatric Nephrology and Transplantation
(CPNT), while CT children were selected from the nephrol-
ogy pediatric clinic, Children’s Hospital, Cairo University.
The study was done from June 2010 to December 2010.
The inclusion criteria for MHD patients included patients
with onset of hemodialysis (HD) below 16 years with at
least 6 months duration on MHD. They were treated with
hemodialysis for 3–4 h three times weekly with a polysul-
fone membrane using bicarbonate-buffered dialysate. The
Duration of hemodialysis was 2.75±1.59 years.
Thirty two MHD patients and 16 CT patients were tak-
ing antihypertensive treatment. None of the patients was
treated with fish oil. All patients were selected to be ambu-
latory, non obese, with BMI below 30 kg/m2 to avoid the
potential confounding associations of obesity and cachexia
with altered adipocytokine levels [26]. None of CKD patient
in any group had cardiovascular events on the basis of
examination and detailed clinical history. Additional exclu-
sion criteria were liver disease and nephrotic syndrome
(defined as daily proteinuria >3.5 g/1.73 m2).
All control subjects (n = 70) were healthy with no clin-
ical signs of vascular or renal disease and no family his-
tory of renal disease as well as lack of medications taken
at the time of the study. Control subjects were selected
to be matched for age and gender to the patient groups,
as well as within the same BMI limits. They were col-
lected from the pediatric clinic of National Research
Centre (NRC), Cairo, Egypt. An informed consent for
genetic studies was obtained from parents of all partici-
pants. The protocol of the study was read and approved
by the Ethics Committee of NRC in Egypt.
Echocardiography
All echocardiographic measurements were performed
according to the recommendations of the American So-
ciety of Echocardiography [27]. Left ventricular mass
(LVM) was calculated according to the formula described
by Devereux et al. [28] and was indexed to height2.7
(LVM index) [28]. The height-based indexing of LVM
was specifically chosen to minimize potential distortions
attributable to extracellular volume expansion (with sur-
face area indexing being weight-sensitive). Left ventricu-
lar hypertrophy (LVH) was defined as LVMI greater than
51g/m2.7
Biochemical markers
Venous blood samples were collected in the morning after
an overnight fast on a midweek dialysis day, before the dia-
lysis session. Three ml of venous blood sample was col-
lected in EDTA vials for the extraction of genomic DNA.
Complete blood count and pre- and post-dialysis kidney
function test were determined by standard laboratory
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cholesterol (TC), triglyceride (TG) and HDL cholesterol
were made by using an Olympus AU400 (Olympus Amer-
ica, Inc., Center Valley, Pa., USA).
The determination of high sensitivity C-reactive protein
(hs-CRP) in serum was performed by solid-phase chemilu-
minescent immunometric assay (Immulite/Immulite 1,000;
Siemens Medical Solution Diagnostics, Eschborn, Germany)
[29].
The assay of human IL6 in serum was performed by
ELISA (Enzyme–Linked Immunosorbent Assay) method
for quantitative measurement of serum IL6 (Ray Biotech,
Inc.) [30].
Assay of serum adiponectin level was done using
ELISA kit (Ray Biotech, Inc.) [31].
Genotyping of ADIPOQ gene
The analysis was carried out on a Light Cycler apparatus
(Roche Molecular Biochemical). Primers of 45T>G SNP
were 5′TCTCTCCATGGCTGACAGTG3′ and reverse pri-
mer 5′CCTTTCTCACCCTTCTCACC3′, while primers of
276G>T SNP were 5′GGCCTCTTTCATCACAGACC3′
and reverse primer 5′AGATGCAGCAAAGCCAAAGT3′
For SNP +45T>G and SNP +276G>T, fragments were
amplified by rapid-cycling in a reaction volume of 20μl
with 0.5μmol/l each primer, 0.15μmol/L anchor and
syber green , 200 ng of genomic DNA, 1 ×DNA Master
mix (Roche Molecular Biochemical) containing nucleo-
tides, Taq DNA polymerase and 10 m M Mg2+. The final
Mg2+ concentration in the reaction mixture was
adjusted to 4 m M. The samples were loaded into glass
capillary cuvettes (Roche Molecular Biochemicals) and
centrifuged. After an initial denaturation step at 95°C
for 5 min, amplification was performed using 50 cycles
of denaturation (95°C for 3 s), annealing (57°C for 12 s
for SNP +45T>G and 55°C for 12 s for SNP +276G>T)
and extension (72°C for 10 s for SNP +45T>G and 72°C
for 8 s for SNP +276G>T) on the Light Cycler. The
temperature-transition rates were programmed at 20°C/s
from denaturation to annealing, 20°C/s from annealing
to extension and 20°C/s from extension to denaturation.
Fluorescence was measured at the end of the annealing
period of each cycle to monitor amplification. After
amplification was completed, a final melting curve was
recorded by heating to 95°C for 30 s with 20°C/s, holding
at 40°C for 30 s with 20°C/s, and then heating slowly
at 0.3°C/s until 80°C. Fluorescence was measured con-
tinuously during the low-temperature ramp. The fluor-
escence signal (F) was plotted in real time against
temperature (T) to produce melting curves for each
sample (F vs T). Melting curves were then converted to
derivative melting curves by plotting the negative de-
rivative of the fluorescence with respect to temperature
against temperature (−(dF/dT) vs T). The entire processtook approximately 30 min, with no separate manipula-
tion of the product necessary [Figure 1] [32].
Statistical analysis
Statistical package for social science (SPSS) program ver-
sion 16.0 was used for analysis of data. Data were sum-
marized as mean±SD, range or percentage. The
Kolmogorov-Smirnov test was used for evaluating the
normality of data. For those data with abnormal distribu-
tion, log transformation was performed before a t-test.
Matching was done by using two main approaches: pair
(individual) matching and frequency matching. The
number of subjects required for each subgroup was
determined by Confidence Intervals. Power analysis was
used to calculate the minimum sample size required to
accept the outcome of a statistical test with a particular
level of confidence. A sample size of 20 will give us ap-
proximately 80% power (alpha = 0.05, two-tail) to reject
the null hypothesis of zero correlation. We used power
calculations performed by the Power and Precision pro-
gram (Biostat) to determine the number of chromosomes
required to detect a significant difference between the
polymorphism frequency in the reference population and
the expected frequency. Power commonly sets at 80%;
however, at that level, a polymorphism would be missed
20% of the time. Data were valuated between the experi-
mental groups by One-Way Analysis of Variance
(ANOVA) followed by Tukey’s multiple comparison
tests. Allele and genotypic frequencies for ADIPOQ45
and 276 alleles were calculated with the gene counting
method. Hardy–Weinberg equilibrium was tested with
the X2 test. Comparison of the categorical data i.e. differ-
ent ADIPOQ genotypes among patients was done by in-
dependent-samples t test where appropriate after
evaluating the normality of data. Fisher’s exact test and
X2 test were done to confirm the results. Multiple linear
regression analysis was performed to assess the influence
of metabolic risk factors and mutant alleles on adiponec-
tin level. A p value of < 0.05 was considered significant.
Results and Discussion
Anthropometric, clinical, and biochemical parameters in
controls and CKD subjects were shown in Table 1.
MHD, CT, and control subjects were comparable for
gender, age and body mass index. The groups also had
comparable blood pressure recordings. Patients receiving
dialysis had higher absolute SBP and absolute DBP than
healthy controls. Plasma creatinine concentration was
higher by design in CKD groups with intermediate values
in CT and highest levels in MHD. As expected, eGFR
was lowest in MHD and within stages 4 and 5 for CT
patients. It was observed that the lipid parameters
namely TC, TG and HDL cholesterol, differ significantly
among the CKD patients when compared to the controls
Figure 1 The homo mutant and the wild types of ADIPOQ 276 gene.
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MHD than in all other groups, while serum TG concen-
tration was higher in CT than in both MHD and control
subjects. Plasma hs-CRP was higher in MHD than in all
other groups while serum IL6 and adiponectin levels
were significantly higher in both stages of CKD children
than in controls with increased level in CT children than
in MHD group (P= 0.01). No significant difference be-
tween male and female CKD patients as regard to serum
adiponectin level.
Distributions of ADIPOQ +45 T>G and ADIPOQ
+276G>T genotypes.
The genotype frequencies in each group satisfied the
Hardy–Weinberg equilibrium. The distribution of
genotype.
The frequencies of the TT, TG, and GG genotypes of +45
T>G gene were 100%, 0%, and 0% in both stages of CKD
children and 100%, 0%, and 0% in the controls, respectively.
The frequencies of the T and G alleles of +45 T>G gene
were 100% and 0% in patients and 100% and 0% in the con-
trols, respectively. This means that the wild type ofADIPOQ +45T>G gene (T) is the main allele for patients
and controls and no significant difference was observed be-
tween them. MHD and CT patients had significantly higher
frequency of the TT genotype of +276G>T gene (P=0.04)
compared with control subjects. The frequency of the T al-
lele carriers was significantly higher in MHD than in healthy
subjects. There was no significant difference between MHD
and CT groups as regard to GT and TT genotypes (P>0.05)
(Table 2).
In order to assess the cumulative effect of ADIPOQ
+276G>T gene polymorphism with other risk factors; we
compared various clinical parameters of the CKD patients
between two genotypic groups, GG and GT+TT (Table 3).
It was observed that neither mean age nor any of the lipid
parameters differs significantly among the two sub-groups
(p> 0.05). Serum adiponectin was significantly higher
(p=0.04) in the GT+TTgroup than in the GG group.
Correlation between serum adiponectin levels and dif-
ferent variables.
In the whole study population, a significant positive
correlations was observed between plasma adiponectin








Age 9.14 ± 7.59 10.62 ± 3.49 10.7 ± 4.51






BMI(kg/m2) 17.64 ± 1.17 18.89 ± 3.00 20.88 ± 1.50
SBP (mmHg) 98.66 ± 6.66 127.13 ± 18.37 b* 94.55 ± 9.80
DBP (mmHg) 64.66 ± 6.67 85.15 ± 13.76 b* 60.59 ± 10.11
Creatinine (mg/dl) 3.93 ± 3.75 a* 6.32 ± 1.55 b* 0.77 ± 0.34
Predialysis urea, (mg/dl) 51.12 ± 10.45 a* 71.56 ± 20.61 b* 7.80 ± 2.64
eGFR, ml_min_1 _1.73m2 15.41 ± 1.76 a** 11.30 ± 3.35 b** 87 ± 8.9








obstructive uropathies 8 6









ACE inhibitors 6 17
Ca channel blockers 10 29
Kt/V 1.69 ± 0.42
Total cholesterol
(mg/dl)
164.44 ± 50.10 193.04 ± 51.37 b* 160.31 ± 18.74
Triglycerides
(mg/dl)
160.78 ± 57.33 a**147.00 ± 66.98 b** 65.31 ± 18.35
HDL cholesterol
(mg/dl)
21.35 ± 1.17a* 27.34 ± 9.88 b* 39.55 ± 7.94
hs-CRP, mg/dl 3.04 ± 3.24 3.62 ± 3.97 b* 1.36 ± 0.67
IL6(pg/ml) 59.50 ± 46.48 a* 19.10 ± 23.68 b** 3.17 ± 1.56
Adiponectin (μg/ml) 154.00 ± 7.18 a** 52.44 ± 19.1 b** 24.80 ± 8.23
Data was evaluated by ANOVA test. Values are presented as means ± SD or
percentage as applicable. CT conservative treatment, MHD maintenance
hemodialysis, BMI body mass index, SBP systolic blood pressure, DBP diastolic
blood pressure, eGFR estimated glomerular filtration rate, ACE angiotensin
converting enzyme, Kt/V adequacy of hemodialysis, hs-CRP high sensitivity
c-reactive protein. a*P< 0.05 or a**P< 0.01vs. control and MHD b*P< 0.05 or
b**P< 0.01 vs. control and CT .








+276 G>T Alleles G 54(84.38%) 73(79.35%) 125(89.29%)
T 10(15.62%) 19(20.65%) b* 15(10.71%)
Genotypes GG 24(75.00%) 32(69.56%) 55(78.57%)
GT 6(18.75%) 9(19.57%) 15(21.43%)
TT 2(6.25%) a* 5(10.87%) b* 0(0%)
+45 T>G Alleles T 64(100%) 92(100%) 140(100%)
G 0(0%) 0(0%) 0(0%)
Genotypes TT 32(100%) 46(100%) 70(100%)
TG 0(0%) 0(0%) 0(0%)
GG 0(0%) 0(0%) 0(0%)
Data was evaluated by the gene counting method. Values were presented as
percentage. CT conservative treatment, MHD maintenance hemodialysis.
aP< 0.05 vs. control and CT, bP< 0.05 vs. control and MHD.
Table 3 Clinical and laboratory characteristics of CKD






Age Years 10.73 ±3.98 10.05 ± 3.15 0.51
LVMI 53.86 ± 9.67 50.86 ± 10.97 0.39
Cholesterol(mg/dl) 186.58 ± 47.22 178.20 ± 60.10 0.66
TG(mg/dl) 154.08 ± 71.73 134.71 ± 42.78 0.40
HDL cholesterol(mg/dl) 24.93 ± 11.29 28.15 ± 13.97 0.45
Adiponectin(μg/ml) 70.21 ± 42.85 90.92 ± 43.15 0.04*
hs-CRP(mg/dl) 3.54 ± 3.72 3.54 ± 4.07 0.99
IL6(pg/ml) 18.80 ± 25.23 24.87 ± 31.67 0.56
Significance was estimated using independent t-test. Data are means ± SD.
LVMI left ventricular mass index, TG triglyceride, hs-CRP high sensitivity C -
reactive protein, IL6 interleukin 6. P is significant if < 0.05.
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relation was found between adiponectin level and hsCRP
concentration (r =−0.27, p= 0.04). Plasma adiponectin
correlated with levels of cholesterol (r =−0.47; p= 0.009)
and HDL cholesterol (r =−0.61; p= 0.0001) levels,
whereas no significant correlation (r = 0.18, p= 0.41) wasobserved between plasma adiponectin and serum trigly-
ceride. No significant correlations were observed be-
tween serum adiponectin level, age, BMI or LVMI.
Significant correlations were observed between serum
adiponectin , eGFR and blood urea (r = 0.45, p= 0.04 and
r =−0.28, p= 0.04) (Table 4).
IL6 was positively correlated with blood urea nitrogen
(r = 0.45, p= 0.007) and hs-CRP(r = 0.45, p= 0.005)
In a backward multiple linear regression model, includ-
ing total cholesterol, HDL cholesterol, hs-CRP, IL6 and
mutant ADIPOQ 276 gene, only IL6(β= 0.85, p= 0.001)
was significantly associated with adiponectin serum
levels (Table 5).
The present study was in agreement with earlier reports
that plasma ADPN was elevated among patients with CKD
compared to the general population and was related to sev-
eral risk factors and inflammatory markers in a way consist-
ent with the hypothesis that this protein might act as a













Mutant ADIPOQ276 gene 0.19 0.43
BMI body mass index, eGFR estimated glomerular filtration rate, hs-CRP high
sensitivity c-reactive protein, IL6 interleukin 6. *P< 0.05 or S**P< 0.001 were
considered significant.
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other hand, genetic variations in the ADIPOQ gene seemed
to have some impact on circulating adiponectin levels in
these patients groups. The adiponectin level was higher in
CT patients than in MHD patients. This might clarify that
MHD patients were more exposed to cardiovascular risk
factors. Previous reports notably agreed with the current
data in indicating lack of increments of circulating adipo-
nectin in renal patients undergoing hemodialysis compared
with conservative treatment, in spite of presumable extreme
reductions of renal function in the hemodialysis groups
[33,34]. In the above studies, it is well possible that lack of
plasma adiponectin increments in hemodialysis resulted
from a decline in adipose tissue contribution with a parallel
relative increment of passive accumulation [33,34].
Whereas hypoadiponectinaemia had been demon-
strated for several groups of patients with increased risk
for CVD [11,13,20-22], the present study demonstrated
markedly elevated plasma adiponectin levels in CKD
patients. Thus, our results confirmed those reported by
Zoccali et al [7], who found markedly elevated adiponec-
tin levels in a group of ESRD patients treated by HD.Table 5 Multiple linear regression analysis correlating
adiponectin level to different variables
Dependent variables ß P-value
Cholesterol −0.30 0.91
HDL cholesterol 0.09 0.41
hs-CRP −0.18 0.27
IL6 0.85 0.001**
Mutant ADIPOQ 276 gene 0.09 0.74
hs-CRP high sensitivity c-reactive protein, IL6 interleukin 6. **P< 0.01 was
considered significant.The reason(s) why ESRD patients had elevated levels of
plasma adiponectin are not completely evident.
Chronic renal failure is one of the diseases state known
to be associated with increased plasma ADPN concentra-
tions; therefore, it represents a useful model for elucidation
of the potential clinical implications of this substance.
Physiologic concentrations of this substance exhibit inhibi-
tory effects on TNF-α-induced monocyte adhesion and ad-
hesion molecule expression [2]. There is evidence that
atherosclerosis is strongly associated with inflammation
among uremic patients [35,36]. If the inflammatory re-
sponse detected in atherosclerotic lesions is effectively
counteracted by ADPN in vivo, then this protein may have
the potential for prevention and/or retardation of athero-
genesis in various diseases, including chronic renal failure.
The directions of the relationships between ADPN and
several metabolic risk factors [36], such as cholesterol,
HDL cholesterol and markers of inflammation (hs-CRP
and IL6), were all in agreement with the hypothesis that
ADPN may have a protective role for the cardiovascular
system among CKD patients.
The present study provided an evidence of association
between a variant in the adiponectin gene and CKD in
children. MHD and CT patients had significantly higher
frequency of the TT genotype of +276G>T gene compared
with control subjects, while no significant difference was
found in the distribution of ADIPOQ +45T>G gene poly-
morphisms between CKD patients and controls, suggesting
that ADIPOQ276 gene polymorphisms may be a signifi-
cant contributor to CKD susceptibility.
How does the 276G4T SNP affect the adiponectin gene
function is still an open question. Although a possible ef-
fect on gene expression of SNPs with no apparently bio-
logical significance cannot be ruled out and, in fact, has
been recently reported also for the adiponectin gene
[35,36]. It appears more likely that this SNP is in linkage
disequilibrium with another mutation either within, or in
other genes close to, the adiponectin gene that deter-
mines its negative effects [32,37,38].
Our findings suggested that genetic variations of the adi-
ponectin gene have a positive impact on plasma adiponectin
levels in CKD patients. Our patients with the relatively rare
GT+TT ADIPOQ 276 genotypes had significantly higher
plasma adiponectin levels than the other genotypes, no sig-
nificant differences in plasma adiponectin levels were noted
for any of the other polymorphisms in this patient group.
This finding was in agreement with data by Menzaghi et al
[20] from non diabetic individuals showing significantly
lower plasma levels of adiponectin in ADIPOQ 276 G/G
homozygotes. Polymorphisms in the ADIPOQ gene had
been shown to correlate with adiponectin serum levels in
previous study in which the expression of the G allele at
SNP +45 T>G was consistently higher than the T allele
among all study subjects [39]. Moreover, Hara et al.
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associated with lower plasma adiponectin concentration in
Japanese population [18].
In the present study, a significant negative correlation
was found between adiponectin and one of biomarkers of
inflammation, hs-CRP and a positive correlation was
observed between plasma IL-6 and ADPN after adjusting
for CRP. While this observation might be explained by the
co linearity between CRP and IL-6, it is pertinent that both
ADPN and IL-6 are adipocyte derived products and their
concordance could represent a co-secretory response after
accounting for the variability in IL-6 levels that is repre-
sented by CRP. Importantly, the inverse correlation of adi-
ponectin and hs-CRP remained statistically significant
even after adjustment for confounders. Thus, our data sug-
gested that hypoadiponectinaemia might also serve as a
marker of increased inflammatory status in CKD patients.
Our results confirmed those recently presented by Ouchi
et al [12] who reported that patients with coronary athero-
sclerosis, showing a reciprocal association of adiponectin
and CRP levels in human plasma. It is believed that adipo-
nectin has anti-inflammatory properties and can counter-
act the pro-inflammatory effects of TNF-a [2] which might
influence the production of IL-6 and CRP. A beneficial
anti-inflammatory role of adiponectin is further supported
by in vivo studies showing that adiponectin prevented
neointimal formation [1].
Conclusions
The present study revealed markedly elevated levels of
plasma adiponectin in CKD pediatric patients. An asso-
ciation between the 276G>T SNP in the adiponectin
gene and CKD in children was found. Genetic variations
of +276G>T SNP in the adiponectin gene seemed to
have a positive impact on plasma adiponectin levels.
The complicated interaction between environmental
factors and ADIPOQ gene polymorphisms in terms of
susceptibility to CKD, especially in ethnically diverse
populations has to be explored.
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